ERBB2 and breast carcinoma: In fact, HER2-positive breast carcinoma patients refractory to trastuzumab treatment, demonstrated a lower α-diversity and reduced abundance of Bifidobacteriaceae, Prevotellaceae, Lachnospiraceae, and Turicibacteraceae compared to individuals who achieved pCR (122).